Carmen Blanco

Oncologia medica.

[Angela Lamarca @DrAngelaLamarca]

Representation from the Comite Nacional de Tumores Biliares #CNTB, our #Spanish Multidisciplinary Group for #BTC, at @myESMO #ESMOGI26 in 📍Munich

Thanks @atuvibi @EBaucellsMolera for the very nice 📸

🙌🏻Wish to join our CNTB?
📝Sign up here (Spain only)
https://t.co/oOoHf2c2Ao

[Carmen Blanco @c_blanco_]

A few years ago we asked whether KRAS could be drugged. Today we are discussing the best sequence of KRAS inhibitors, chemotherapy and combinations. Exciting times ahead, with many challenges still to solve. #ESMOGI26 #PancreaticCancer #KRAS

[Oriol Mirallas MD @DrMirallas]

#ASCO26
💥 Plenary Sessions
THE most expected #KRAS @RevMedicines

5. RASolute 302: Phase 3 of Daraxonrasib, a RAS(ON) multi-selective inhibitor vs chemotherapy in previously treated metastatic pancreatic adenocarcinoma (mPDAC)

🗣️ Dr. Wilson @DanaFarber
✅ mOS 13.2 vs 6.7m, HR 0.40 😱😱
✅ mPFS 7.3 vs 3.5m, HR 0.45
✅ ORR 33.2 vs 11.8m

☣️ Most common tox #rash and #stomatits
☣️ >=G3 43.6 vs 57.5%

A clear positive study❗

@ASCO @myESMO @_SEOM @VHIO @UTMDAnderson @EileenMOReilly
#OncoAlertAF

[Erman Akkus @Erman_Akkus]

🎯Claudin18.2 targeting in pancreatic cancer
#ASCO26

➡️First line, claudin18.2/cd3 bispecific ab + GnP
✅ORR: 59.8%
✅mPFS: 8.7 mo, mOS: 15.8 mo

#cancer #oncology #MedX #pancreatic #GI @OncoAlert

[Erman Akkus @Erman_Akkus]

🚀Daraxonrasib curves @NEJM 👇
2L of metastatic pancreatic cancer
#ASCO26

https://t.co/JuVXy9q39c

#cancer #oncology #pancreatic #MedX @OncoAlert @realbowtiedoc @DrVilmaPBarcia

[Yakup Ergün @dr_yakupergun]

About 25 years in pancreatic cancer, what we’ve really done is the same: rearranging treatment sequence and intensity.

For the first time, that cycle may be breaking👇

Daraxonrasib (pan-RAS inh)
was reported to nearly double OS compared with chemotherapy.

https://t.co/GaDveHpf2v

[OncoDaily GI @OncoDailyGI]

💥 Interview with Shiraj Sen | The Future of RAS-Targeted Therapy in Pancreatic Cancer

In a written interview with OncoDaily, Shiraj Sen, Principal Investigator of the phase III RASolute 303 trial and Director of Clinical Research at NEXT Oncology (Dallas), discussed the rationale and clinical implications of daraxonrasib (RMC-6236), a multi-selective RAS(ON) inhibitor developed by Revolution Medicines, in metastatic pancreatic ductal adenocarcinoma.

The discussion covered sustained RAS suppression in a disease where ~92% of tumors harbor RAS mutations, the three-arm design of RASolute 303 comparing daraxonrasib alone or with chemotherapy against standard care, and early clinical signals supporting this strategy.

@oncodaily @ShirajSenMDPhD @NEXT_Oncology @GarridoLagunaMD @DrGManji @AlexSpiraMDPhD @NiloferAzad @DrShubhamPant

🔗https://t.co/FOhnMPrXOk

#PancreaticCancer #PDAC #RAS #ClinicalTrials #GIOncology #OncoDaily

[Enes Erul MD @ErulEnes]

My biggest takeaway: one of the strongest protectors against burnout is remembering that being an oncologist is not just a job—it’s a purpose of life. Reconnecting with our “why” matters. #advocacy #policy #oncology #HealthPolicy @healthpolicycop @ASCO

[Eduardo Terán @EduardoTB94]

💥Glad to share our latest paper on biomarker overlap in GEA and its predictive/prognostic implications.
💊 First-line treatment in advanced GEA is increasingly complex.
🕵️‍♂️ Important insights in overlapping populations: PD-L1, CLDN18.2 and HER2.
🙏 Participating centres! @myESMO

[Eduardo Terán @EduardoTB94]

TTD Young Researchers @GrupoTTD
Que buen equipo 🧑‍🧑‍🧒‍🧒🤩

[Arndt Vogel @ArndtVogel]

CTx vs CTx + atezolizumab as adj. therapy for stage III deficient DNA MSI/ dMMR mCRC
🔥#ASCO25 Plenary session🔥
🔎Alliance A021502; ATOMIC
👉mDFS 86.4 vs 76. 6, HR 0.5
👉Benefit in all subgroups, OS not yet mature
👉Manageable safety profile
🧐 Practice changing, new SOC
@myESMO

[Nieves Martinez Lago MD PhD @DraMartinezLago]

#TTDUpdates #ASCO2025
Encorafenib, Cetuximab, and mFOLFOX6 vs. SOC in 1L BRAF V600mt mCRC

https://t.co/DUMuJ9EzwY

✅ ORR: OR 2.44 (P<0.001)
✅ PFS: 12.8 vs 7.1 mo (HR 0.53; P<0.001)
✅ OS: 30.3 vs 15.1 mo (HR 0.49; P<0.001)

[Erman Akkus @Erman_Akkus]

🏥Treatment of anal SCC in specific patient groups
2 papers in @myESMO GI Oncology

✅Older patients and patients with frailty (algorithm👇)

✅HIV infection should not lead to dose-reduced CRT or distinct systemic therapies for fit patients with CD4 counts >400 cells/mm3 and/or undetectable HIV viral load

👉https://t.co/x8soPkk0tE
👉https://t.co/AhOWyxUIyo

@OncoAlert @realbowtiedoc @BbaharK #cancer #oncology #MedX

[Janira Navarro @Janiranavarro]

Problem based approach to liver tumor diagnosis
"Garden variety Adenocarcinoma" in the liver

Dr. Bellizzi #USCAP25 #pathology #PathX

[Erman Akkus @Erman_Akkus]

📢DESTINY-Gastric04

➡️Phase-3
➡️HER2-positive gastric/GEJ
adenocarcinoma
➡️2L
➡️Trastuzumab-deruxtecan VS. ramicurumab-paclitaxel
✅Statistically significant and clinically meaningful improvement in OS with T-Dxd

👉https://t.co/0DcO1KgCHT

@OncoAlert #cancer #oncology #MedX

[Arndt Vogel @ArndtVogel]

Encorafenib, cetuximab and chemotherapy in BRAF-mutant colorectal cancer:
https://t.co/ujDekXSi1d
@NatureMedicine
🔎BREAKWATERa phs 3 trial
👉ORR 60 vs 40.0%
👉DoR 13.9 vs11.1 mo
👉OS NE vs 14.6
🧐New SOC for BRAF mutant CRC
@myESMO

[Erman Akkus @Erman_Akkus]

🏥Liver Transplantation for Hepatocellular Carcinoma
@JCO_ASCO

✅Immunotherapy, local treatments and improved responses ➡️ expanding eligibility
❗️Challenges: Defining criteria, designing trials, biomarkers and organ shortage

@ArndtVogel @JCOOP_ASCO @ASCO @OncoAlert @realbowtiedoc #cancer #oncology #liver #MedX

[Erman Akkus @Erman_Akkus]

🔵Immune-mediated liver injury by ICIs
@NatRevGastroHep

✅From mechanisms to treatment

👉https://t.co/pmgLjM2L93

@OncoAlert #cancer #oncology #immunotherapy #MedX

[Erman Akkus @Erman_Akkus]

🧬Cancer types and genes associated with germline mutations 👇
@ASCO

@OncoAlert @JCOPO_ASCO #cancer #oncology #genetics #MedX

[Carmen Blanco @c_blanco_]

Brillante charla de @elena_elez sobre liderazgo 😊